Ketorolac Trometamol Misom (Ketorolac Trometamol)

The active ingredient, Ketorolac Trometamol, blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes in ocular tissues, preventing the formation of prostaglandins that drive inflammation and pain. By lowering prostaglandin levels, the drug reduces vascular permeability, edema, and nociceptive signaling within the eye.

The specific dosing regimen for Ketorolac Trometamol Misom is determined by the prescribing ophthalmologist based on the type of surgery, severity of inflammation, and individual patient factors. The prescriber will provide exact instructions on the number of drops, frequency, and duration of therapy.

The safety of Ketorolac Trometamol in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Ketorolac Trometamol is a non‑steroidal anti‑inflammatory drug, offering anti‑inflammatory and analgesic effects without the steroid‑related risks of cataract formation or intraocular pressure rise. Compared with steroid eye drops, it has a lower risk of steroid‑induced glaucoma but may be less potent for severe uveitis, making it suitable for many postoperative and mild‑to‑moderate inflammatory conditions.

Ketorolac Trometamol Misom should be stored at room temperature, below 25 °C, in its original packaging to protect it from light and moisture. The container should be tightly closed, and any unused portion should be discarded after the labeled expiry date to ensure efficacy and safety.

The product is applied as eye drops. The prescriber will instruct the patient on the number of drops per eye, the frequency (e.g., one to two drops several times daily), and the duration of treatment. Proper hand hygiene and avoidance of contact between the dropper tip and the ocular surface are essential.

Serious adverse events, though rare, include corneal ulceration, severe allergic reactions such as angioedema, marked increases in intraocular pressure, and rare systemic hypersensitivity reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent pain, vision changes, or signs of a severe allergic response.

Ketorolac Trometamol Misom is contraindicated in individuals with known hypersensitivity to ketorolac, other NSAIDs, or any component of the formulation. It should also be avoided in patients with active ocular infections, severe corneal disease, or those using other ocular NSAIDs unless specifically directed by a healthcare professional.